ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

HDM2017

A development code.

Its studies are mostly in Colorectal Neoplasms, led by Huadong Medicine.

Furthest: phase 2, since May 27, 20262 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Huadong Medicine22 open or runningphase 2since May 27, 2026Nov 24, 2025Dec 31, 2026phase 1 · NCT07274085

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 24, 2025First study: phase 1 study in Solid TumorsFirst studyNCT07274085 · 96 planned · China
  2. May 27, 2026Phase 2 study in Colorectal Cancer MetastaticPhase 2 reachedNCT07621159 · 120 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Solid TumorsNCT07274085
  2. Nov 1, 2027Primary completion: phase 2 study in Colorectal Cancer MetastaticNCT07621159

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07621159Colorectal Cancer Metastatic · China2Not yet recruitingNov 1, 2027120
NCT07274085Solid Tumors · China1RecruitingDec 31, 202696

How it is read

Names in the registry

  • “HDM2017”, 2 entries

Codes read as this program: HDM2017.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.